Physician profile
Lawrence E Neack
NPI 1225094568
$376.34
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.45 · 2020: $56.63 · 2021: $184 · 2022: $39.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $88.98 | 2021-2022 | |
| Novo Nordisk INC | $58.44 | 2020-2021 | |
| Amgen INC. | $49.89 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $39.32 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $37.27 | 2021 | |
| Pfizer INC. | $32.46 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.48 | 2021 | |
| Amarin Pharma, INC. | $14.64 | 2020 | |
| Astellas Pharma US INC | $14.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.01 | 2021 | |
| Lilly USA, LLC | $11.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Neack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.